Brivaracetam 357336-20-0 Nootropics Drug Raw Powder 99% Purity USP Standard

Basic Information
Place of Origin: CHINA
Brand Name: TINGYI
Certification: GMP , ISO 9001:2008
Model Number: 357336-20-0
Minimum Order Quantity: 10g
Price: Contact Me
Packaging Details: Disguised Package
Delivery Time: 2 Working Days
Payment Terms: Bank Transfer - Bitcoin - Western Union - MoneyGram
Supply Ability: 100 KG/Month
Product Name: Brivaracetam CAS: 357336-20-0
Appearance: White Powder Usage: Nootropics Drug
Shipping Method: EMS, HKEMS, FEDEX, DHL, UPS, Aramex, ETC Synonym: UCB-34714
High Light:

pharmaceutical active ingredients

,

pharmaceutical fine chemicals

Product Details

Product Name

Brivaracetam ; (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;UCB-34714

CAS

357336-20-0

Molecular Formula

C33H41N3O10S2

Molecular Weight

703.83
Molecular Structure Brivaracetam 357336-20-0 Nootropics Drug Raw Powder 99% Purity USP Standard 0

Assay

99%

Appearance

White off-white crystalline powder

Grade Standard

Medicine Grade

 

 

Brivaracetam Description

 

       The precise mechanism by which brivaracetam exerts its antiepileptic activity is unknown. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the antiepileptic effect.


       Brivaracetam is a prescription medication used with other medicines to treat partial-onset seizures in people 16 years of age and older with epilepsy. Brivaracetam belongs to a group of drugs called antiepileptics. These work by reducing the frequency of seizures.


       This medication comes in a tablet and solution form and is usually taken 2 times a day by mouth with or without food. The brivaracetam tablets should be swallowed whole with liquid. Do not crush or chew brivaracetam tablets before swallowing.


       This medication is also available in an injectable form to be given directly into a vein (IV) by a healthcare professional.

 

       Brivaracetam, a chemical analog of Levetiracetam, is a racetam derivative with anticonvulsant effect. It is used for the treatment of partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs. The exact mechanism of brivaracetam's anti-epileptogenic activity is unknown. What is known is thatbrivaracetam binds SV2A with high affinity. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A. Brivaracetam can also inhibit Na+ channels which may also contribute to its anti-epileptogenic action .

 

 


Dosing

 

Typical dosing instructions:
The dose usually begins at 50 mg twice a day.
It can be lowered to 25 mg twice a day for slower increases.
The dose can be increased gradually to 100 mg twice a day.
People with impaired or altered liver function are given lower doses.The dose usually begins at 25 mg twice a day. It may be increased to 75 mg twice a day.
Briviact will be available as tablets, an oral solution, and an injection which can be used temporarily when oral forms are not possible.
Dosage strengths:
Tablets: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg
Oral solution: 10 mg per ml
Injection: 50 mg per 5 ml, in single dose vials

 

 

 

Storing:
Keep the medicine at 25°C (77°F) or between 15°C to 30°C (59°F to 86°F).
Throw away any unused Briviact oral solution 5 months after the bottle was first opened.
The vial of medicine for the injection form is intended to be used only once. Do not save any unused open drug for the injection form.

 

 

 

Function:

1.Improved Memory
2.Increased Learning Ability
3.Improved Cognitive Processing
4.Heightened Reflexes
5. Heightened Perception
6. Reduced Anxiety
7. Reduced Depression

 

        Brivaracetam is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs. No data are available for its effectiveness and safety in patients younger than 16 years.Coadministration of brivaracetam with carbamazepine may increase exposure to carbamazepine-epoxide, the active metabolite of carbamazepine, and could theoretically lead to reduced tolerability.

 

        Coadministration of brivaracetam with phenytoin may increase phenytoin levels. Coadministration of other antiseizure drugs are unlikely to affect brivaracetam exposure. Brivaracetam provides no added therapeutic benefit when administered in conjunction with levetiracetam that acts on the same protein.

 

Brivaracetam 357336-20-0 Nootropics Drug Raw Powder 99% Purity USP Standard 1

Brivaracetam 357336-20-0 Nootropics Drug Raw Powder 99% Purity USP Standard 2

 


 

Contact Details
Sales Manager

WhatsApp : +8613657291547